Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Apr 1;3(4):e202370.
doi: 10.1001/jamanetworkopen.2020.2370.

Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis

Anees Bahji  1   2 , Callum Stephenson  3 , Richard Tyo  2 , Emily R Hawken  2 , Dallas P Seitz  1   2   4
Affiliations
Meta-Analysis

Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis

Anees Bahji et al. JAMA Netw Open. .

Abstract

Importance: Cannabis withdrawal syndrome (CWS)-a diagnostic indicator of cannabis use disorder-commonly occurs on cessation of heavy and prolonged cannabis use. To date, the prevalence of CWS syndrome has not been well described, nor have the factors potentially associated with CWS.

Objectives: To estimate the prevalence of CWS among individuals with regular or dependent use of cannabinoids and identify factors associated with CWS.

Data sources: A search of literature from database inception to June 19, 2019, was performed using MEDLINE, Embase, PsycINFO, Web of Science, the Cumulative Index to Nursing and Allied Health Literature, ProQuest, Allied and Complementary Medicine, and Psychiatry online, supplemented by manual searches of reference lists of included articles.

Study selection: Articles were included if they (1) were published in English, (2) reported on individuals with regular use of cannabinoids or cannabis use disorder as a primary study group, (3) reported on the prevalence of CWS or CWS symptoms using a validated instrument, (4) reported the prevalence of CWS, and (5) used an observational study design (eg, cohort or cross-sectional).

Data extraction and synthesis: All abstracts, full-text articles, and other sources were reviewed, with data extracted in duplicate. Cannabis withdrawal syndrome prevalence was estimated using a random-effects meta-analysis model, alongside stratification and meta-regression to characterize heterogeneity.

Main outcomes and measures: Cannabis withdrawal syndrome prevalence was reported as a percentage with 95% CIs.

Results: Of 3848 unique abstracts, 86 were selected for full-text review, and 47 studies, representing 23 518 participants, met all inclusion criteria. Of 23 518 participants included in the analysis, 16 839 were white (72%) and 14 387 were men (69%); median (SD) age was 29.9 (9.0) years. The overall pooled prevalence of CWS was 47% (6469 of 23 518) (95% CI, 41%-52%), with significant heterogeneity between estimates (I2 = 99.2%). When stratified by source, the prevalence of CWS was 17% (95% CI, 13%-21%) in population-based samples, 54% in outpatient samples (95% CI, 48%-59%), and 87% in inpatient samples (95% CI, 79%-94%), which were significantly different (P < .001). Concurrent cannabis (β = 0.005, P < .001), tobacco (β = 0.002, P = .02), and other substance use disorders (β = 0.003, P = .05) were associated with a higher CWS prevalence, as was daily cannabis use (β = 0.004, P < .001).

Conclusions and relevance: These findings suggest that cannabis withdrawal syndrome appears to be prevalent among regular users of cannabis. Clinicians should be aware of the prevalence of CWS in order to counsel patients and support individuals who are reducing their use of cannabis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bahji reported receiving a Canadian Institutes of Health Research Master's Student scholarship during the time the manuscript was drafted. Dr Seitz reported participating as a site investigator for a clinical trial sponsored by Hoffmann La Roche. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. PRISMA Flowchart of Study Selection
Search and selection process applied during the systematic review.
Figure 2.
Figure 2.. Prevalence of Cannabis Withdrawal in People With Cannabis Use Disorder
Prevalence of cannabis withdrawal symptoms across 3 clinical settings: population-level samples, outpatient clinical samples, and inpatient clinical samples. The studies by Smith et al (2013), Mennes et al (2009), and Vorspan et al (2010) included 2 or more substudies.
See this image and copyright information in PMC

References

    1. Degenhardt L, Charlson F, Ferrari A, et al. ; GBD 2016 Alcohol and Drug Use Collaborators . The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):-. doi:10.1016/S2215-0366(18)30337-7 - DOI - PMC - PubMed
    1. Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. J Addict Med. 2011;5(1):9-15. doi:10.1097/ADM.0b013e31820cdd57 - DOI - PMC - PubMed
    1. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227. doi:10.1056/NEJMra1402309 - DOI - PMC - PubMed
    1. Carvalho AF, Stubbs B, Vancampfort D, et al. . Cannabis use and suicide attempts among 86,254 adolescents aged 12-15 years from 21 low- and middle-income countries. Eur Psychiatry. 2019;56:8-13. doi:10.1016/j.eurpsy.2018.10.006 - DOI - PubMed
    1. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19(3):233-238. doi:10.1097/01.yco.0000218592.00689.e5 - DOI - PubMed